Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026Mounjaro Maker Eli Lilly Improves In Quality As Bof…

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
Healio

Q&A: How to guide discussions about women’s supplement use

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Courtney Cameron, PharmD, BCACP, about tips for discussing supplement ...